Posted on 23 January 2013.
Good performance likely from pharma in Q3: Nirmal Bang
Cipla : Decline in Lexapro revenue due to additional competition (~USD 22mn-USD 25mn in2QFY13) may lead to a sequential drop in revenue. Domestic revenue is likely to trail the industry's growth. With lower Lexapro sales, we expect the margins to drift …
Full News here – Read more on Moneycontrol.com